Compare STAA & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | ODTX |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1995 | 2025 |
| Metric | STAA | ODTX |
|---|---|---|
| Price | $22.66 | $24.63 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $22.81 | N/A |
| AVG Volume (30 Days) | ★ 874.6K | 149.1K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $90.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $15.10 |
| 52 Week High | $35.87 | $29.05 |
| Indicator | STAA | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 49.69 |
| Support Level | $23.27 | $22.89 |
| Resistance Level | $24.26 | $28.53 |
| Average True Range (ATR) | 0.82 | 2.15 |
| MACD | 0.17 | -0.27 |
| Stochastic Oscillator | 70.13 | 14.03 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.